Hi , I was diagnosed October 2015. I am waiting to see a specialist Dermatologist In May.
I am currently using Dobovet Gel and Dermovate cream and Ointment. Would welcome any tips or advice. I have not had definitive diagnosis but due to my symptoms suspect I have Pustular  as only on my palms, soles and scalp. It itches like crazy and is painful.

This study looked at GSK2586184 a JAK1 inhibitor for the treatment of psoriasis.

Quote:

---

Background:
GSK2586184 is a selective oral Janus kinase (JAK)1 inhibitor being evaluated as a treatment for moderate-to-severe plaque-type psoriasis.

Objectives:
To assess the relationship between dose of GSK2586184 and clinical response, primarily by the Psoriasis Area Severity Index (PASI).

Methods:
Sixty patients with moderate-to-severe plaque psoriasis were randomized to cohort A: 100 mg, 200 mg or 400 mg GSK2586184 twice daily or placebo; and eight were randomized to open-label cohort B, a small exploratory cohort treated with 400 mg GSK2586184 twice daily, to explore differential gene expression.

Results:
At week 12, a 75% reduction in PASI (PASI 75) response rates in the intent-to-treat population were 0% in the placebo group compared with 13%, 25% and 57% in the 100 mg, 200 mg and 400 mg GSK2586184 twice-daily groups, respectively. Increases in the proportion of PASI 75 responses were seen across all dose levels by week 4. Improvement in itch and quality of life were observed at all doses relative to placebo with the greatest improvement seen in the 400-mg dose group. Overall, the incidence of adverse events (AEs) was similar across treatment groups, and no relationship between frequency of AE and GSK2586184 dose was identified. Differential gene expression was observed in involved and uninvolved skin at baseline and in involved skin after 2 weeks of treatment with GSK2586184.

Conclusions:
Our study demonstrates that 12 weeks of treatment with GSK2586184 resulted in clinical improvement and was generally well tolerated in patients with moderate-to-severe plaque-type psoriasis.

This study looked at the relationship between the serum total bilirubin and inflammation in patients with psoriasis.

Quote:

---

Background:
Psoriasis is a chronic and recurrent inflammatory skin disease. Previous studies have shown that bilirubin has anti-inflammation and antioxidant effects. However, the various roles of bilirubin in psoriasis patients are still unclear.

Objective:
To investigate the serum total bilirubin (TB) level in the individuals with psoriasis vulgaris and further evaluate the relationship between serum TB concentration and C-reactive protein (CRP) to clarify the effect of bilirubin on inflammation.

Methods:
A total of 214 patients with psoriasis vulgaris and 165 age- and gender-matched healthy control subjects were recruited. The peripheral leukocyte count (white blood cell, WBC) and differential, serum biochemical and immunologic indexes including serum TB, immunoglobulin (Ig) G, IgA, IgM, complement C3 and C4, as well as serum CRP concentrations were measured.

Results:
Results showed that the serum TB level decreased significantly and peripheral WBC, neutrophil, and serum CRP concentrations increased significantly in patients with psoriasis vulgaris. Meanwhile, the serum CRP was negatively correlated with serum TB levels but positively correlated with peripheral WBC and the Psoriasis Area and Severity Index (PASI). Logistic regression analysis showed that the serum TB was a protective factor for psoriasis vulgaris.

Conclusion:
The present study suggests that lower serum TB is associated with the enhancement of the inflammatory response in psoriasis vulgaris. Therefore, lower serum TB has a prognostic significance for worsening psoriasis vulgaris. Bilirubin may play a crucial role in inflammation by contributing to the inhibition of the inflammatory response.

I've had Psoriasis and psoriatic arthritis for several years. I was on Humira for the last two years, and recently switched to Stelara. The symptom I am having has been consistent with both medications. It could be really common, I just don't know. That's why I'm here    My knees are 100% clear. However, if I kneel down, or if the skin rubs on the lower part of the kneecap in a certain way, it feels like I'm rubbing an open wound. It is super painful. It's not a "sore" feeling, but more like a burning. Its like I have a sore under my clear skin. I really hope somebody knows what in talking about, and if there's any known way to get relief. 

Thanks!

Hi Members 
I have  just  gone  through a relapse  ( first  time  ) .My  first  year  of  it  .Im 67  Things were  going good  my back all cleared  , arms  . Just  some old  stuff  on my  legs  , then  pow  bumps  rash  on  lower  back and  buttocks  .Keep thinking  what  brought this  on ? .Food ,red wine  , a few  shrimp ?
I'm stumped  its  my  first  year /Any  thoughts appreciated  .Is this  a  typical  .....

Inflectra a biosimilar of Remicade has been given FDA approval for psoriasis and psoriatic arthritis.

Quote:

---

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. Inflectra is biosimilar to Janssen Biotech, Inc.’s Remicade (infliximab), which was originally licensed in 1998.

The FDA’s approval of Inflectra is based on review of evidence that included structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Inflectra is biosimilar to Remicade. Inflectra has been approved as biosimilar, not as an interchangeable product.

The most common expected side effects of Inflectra include respiratory infections, such as sinus infections and sore throat, headache, coughing and stomach pain. Infusion reactions can happen up to two hours after an infusion. Symptoms of infusion reactions may include fever, chills, chest pain, low blood pressure or high blood pressure, shortness of breath, rash and itching.  

Inflectra contains a Boxed Warning to alert health care professionals and patients about an increased risk of serious infections leading to hospitalization or death, including tuberculosis, bacterial sepsis, invasive fungal infections (such as histoplasmosis) and others. The Boxed Warning also notes that lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor blockers, including infliximab products such as Inflectra. Other serious side effects may include liver injury, blood problems, lupus-like syndrome, psoriasis, and in rare cases nervous system disorders. The drug must be dispensed with a patient Medication Guide that describes important information about its uses and risks.

Inflectra is manufactured by Celltrion, Inc, based in Yeonsu-gu, Incheon, Republic of Korea, for Hospira, of Lake Forest, Illinois.

Just been reading about tests that went on a few years back where they injected bee venom into plaques with good results, has anyone else heard of this?!

This study of Baricitinib is a randomized phase 2b trial for psoriasis.

Quote:

---

Background:
Plaque psoriasis is a chronic and often debilitating skin disorder and proinflammatory cytokines are known to play a key role in the disease process.

Objectives:
To evaluate the safety and efficacy of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis in a randomized, double-blind, placebo-controlled, dose-ranging phase 2b study.

Methods:
Patients were randomized (n = 271) to receive placebo or oral baricitinib at 2, 4, 8 or 10 mg once daily for 12 weeks (Part A). Dose adjustment for 12 additional weeks was based on percentage improvement in the Psoriasis Area and Severity Index (PASI) score. The primary end point was Psoriasis Area and Severity Index (PASI) 75% (PASI-75) at 12 weeks for North American patients (n = 238); secondary end points were safety and efficacy measures in the entire population.

Results:
At week 12, more North American patients in the 8-mg (43%) and 10-mg (54%) baricitinib groups than in placebo group (17%; P < 0·05) achieved PASI-75. All baricitinib-treated groups had greater mean changes from baseline in their PASI scores (P < 0·05) at 12 weeks and (except 2 mg) had higher rates of PASI-50 than the placebo group; statistically significant PASI-90 responses were achieved in the 8-mg and 10-mg groups at 8 and 12 weeks. More than 81% of PASI-75 responders maintained their scores through 24 weeks. During Part A, study discontinuations due to adverse events (AEs) were 0%, 0%, 2·8%, 6·3% and 5·8% and treatment-emergent AE rates were 44%, 50%, 47%, 58% and 64% for placebo and 2-, 4-, 8- and 10-mg baricitinib groups, respectively. No opportunistic infections were observed in any treatment group. Dose-dependent changes in laboratory values were observed.

Conclusions:
Patients with moderate-to-severe psoriasis treated with baricitinib for 12 weeks achieved significant improvements in PASI-75.

Pfizer have announced top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis.

Quote:

---

Pfizer Inc. announced today top-line results from its first Phase 3 study investigating tofacitinib for the treatment of psoriatic arthritis, Oral Psoriatic Arthritis triaL (OPAL) Broaden. This study evaluated the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adult patients with active psoriatic arthritis (PsA) who had an inadequate response to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and who were tumor necrosis factor inhibitor (TNFi)-naïve. OPAL Broaden met its primary efficacy endpoints demonstrating that both tofacitinib 5 mg BID and 10 mg BID were superior to treatment with placebo at 3 months as measured by American College of Rheumatology 20 (ACR20) response and Health Assessment Questionnaire Disability Index (HAQ-DI) score.

“As a chronic inflammatory disease, psoriatic arthritis can have a significant impact on a person’s daily life. Despite available therapies, including biologic and oral treatments, there remains an unmet need for additional options,” said Michael Corbo, Category Development Lead, Inflammation & Immunology, Pfizer Global Innovative Pharmaceuticals Business. “The results seen in the OPAL Broaden study are encouraging as they suggest that tofacitinib may have the potential to offer an additional effective oral option for patients living with psoriatic arthritis. We look forward to sharing detailed results at a future scientific meeting.”

OPAL Broaden is a Phase 3 placebo-controlled study that investigated the efficacy and safety of tofacitinib 5 mg and 10 mg BID in treating the signs and symptoms of PsA, and improvement in physical function in patients with active PsA who had an inadequate response to at least one csDMARD due to lack of efficacy or adverse event, and who were TNFi-naive. Patients enrolled in the study were required to be on one csDMARD as background therapy and continue that dose for the duration of the study. The study also included adalimumab 40 mg subcutaneously administered every 2 weeks (q2 wk) as an active control arm. However, this study was not powered for non-inferiority or superiority comparisons between tofacitinib and adalimumab. A total of 422 patients were randomized in a 2:2:2:1:1 ratio to the following treatment arms: tofacitinib 5 mg BID, tofacitinib 10 mg BID, adalimumab 40 mg q2 wk, placebo to tofacitinib 5 mg BID and placebo to tofacitinib 10 mg BID treatment sequences.

Overall safety findings in this study were consistent with those observed in the broader rheumatology clinical development program for tofacitinib. All treatment groups had similar rates of treatment-emergent adverse events, serious adverse events, and discontinuations due to adverse events over the 12-month duration of the study. Serious adverse events observed were similar to those seen in other clinical development programs for tofacitinib.

Hi

Been lurking for a couple of days so thought I would sign up.

My names Sam and I have what I would describe as Chronic Psoriasis covering about 90% or more of my body.

I'm 26 years old and it came out at the age of about 22 when I went through a bad split up with the mother of my child. (stress induced?)

I have tried all the steroid creams from my doctor and also the moisturiser creams - Doublebase etc.

But now i've decided it's finally time to try and get my Psoriasis under control, It's had a hold on me for too long and affects my self confidence way too much!

I like the idea of the natural treatment route and as a result of reading this forum will be trying Hemp oil, Coconut oil and possibly Bicarbinate of Soda.

Very recently (last couple of weeks) I have been using a natural cream called Sorion, It's very expensive from Amazon BUT it has so far had the best results so i'm going to keep on using it too.

I'd like to share some pictures if i'm allowed to? Hopefully then I can track my own progress.

Thanks for reading.

After lurking here the past month or so, I've decided to take the plunge and introduce myself! 
I've spent the last 20 years living with psoriasis being diagnosed at age 15. Of course went through all the creams and such for quite a few years. But the psoriasis gradually spread from my arms to my legs. Pregnancy 11 years ago completely cleared the psoriasis up, but alas it came back with vengeance! Arms, legs, hands, feet and face were all affected. Thus started my journey with MTX. 
MTX worked fairly well for me for quite a few years. It keept everything clear with the exception of my arms which I could live with. About 3 years ago the side effects of MTX seemed to start to get worse. Instead of being tired and nauseous for one day it was stretching into two or three. And the psoriasis started to pop back up everywhere. But I contined taking it until last summer. I started feeling sick and tired all the time. Psoriasis was getting worse and worse. A lot of pain which was really really starting to impact my every day life. 
So back to my derm last fall where she switched up the dose of MTX, but that didn't help. She then set me up with Stelara, which my insurance has decided not to cover but thank goodness I was approved for long term compassionate care. I just had my second injection on friday, and can't even begin to believe the difference this drug is making in my life!!!!! 
No one else in my family not do any of my friends have this disease. A lot of times I feel so very alone, like no one can truly understand what it is I go through on a daily basis. Coming here and reading all of your posts have helped me feel like I'm not so alone!
Thank you!!

Hi, I've been taking Acitretin for about 7 weeks now and all I can say about it so far is that I seem to have had a lot of the side effects without any of the benefits.

I have had Psoriasis for about 20 years and over the last 5 or so it's got gradually worse. I've had a few light treatments that have worked but it always came back. My consultant advised Acitretin so I thought I'd give it a go.

I've read that it's slow but I've been on it for 7 weeks now and instead of seeing improvements, all I've seen is a dramatic worsening! It now almost completely covers my buttocks and legs and is slowly making its way up my stomach, back and arms.

I can cope with some of the side effects - dry lips and nostrils with the accompanying nose bleeds, but some of the others are getting to me. I'm almost constantly cold (yet when I'm sat my psoriasis is hot and sweaty), my skin feels very smooth and almost waxy or like it has a thin film of plastic on it - including the roof of my mouth and yet my plaques are now paper thin and get cut at the slightest scratch. But like I said the worst has to be the huge flare that just seems to be getting worse. There are new patches appearing on a daily basis and they all seem to want to join up and have a party!

Is this normal for Acitretin? I am meeting my derm on Tuesday and I don't know what to say. Do I stick with it for another 8 weeks or do I ask for something else?

I hope some of you kind folks can give me some advice.

Thanks.

Hello everyone. I look forward to participating in the forums. I've had P from the age of 7 and have learned to live with it without too much trouble, even though it fluctuates in its severity. We all have to live with it, so I expect there are many coping methodologies in play. I can't say it has not affected my life or confidence at times, but age brings tolerance of others' intolerance so I don't go out of my way to hide it. Have a great day. 

I just did my 3rd starter doses of Cosentyx today. I seem to be having some success as I am starting to clear a little bit already. I have taken Humira, Embrel, and Methotrexate over the last six years. Each worked initially for me, but after some time I would have to take them in conjunction with Methotrexate to clear completely. I am hoping this works without the Methotrexate. So far, I have not felt any side effects from the Cosentyx. I will update my progress weekly for anyone that is curious. 

Best Regards,

Cotton

Hello,

My name in Michele, I'm 30 and I have P. I read a lot of info posted here and I'm glad this support group exists. I'm sure I will find a lot of interesting things around here.

Thank you all for being here for people like me!

PS: My English is not very good, but I will try to do my best. Who knows, maybe it will be improved, having a lot of nice people around     


Have a nice day my new friends!

Dr. Reddy's Laboratories and XenoPort, Inc announce they have entered into a license agreement pursuant to which Dr. Reddy's Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort's clinical-stage oral new chemical entity, XP23829 for psoriasis.

Quote:

---

Dr. Reddy's Laboratories and XenoPort, Inc. announced today that they have entered into a license agreement pursuant to which Dr. Reddy's Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort's clinical-stage oral new chemical entity, XP23829. Dr. Reddy's Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis (MS).

Under the terms of the agreement, Dr. Reddy's Laboratories will receive exclusive U.S. rights to develop and commercialize XP23829 for all indications. In exchange for these rights, XenoPort will receive a $47.5 million up-front payment and an additional $2.5 million for transfer of certain clinical trial materials to Dr. Reddy's Laboratories. XenoPort will also be eligible to receive up to $190 million upon the achievement by Dr. Reddy's Laboratories of certain regulatory milestones, which could be achieved over a period of several years. In addition, XenoPort will be eligible to receive up to $250 million upon the achievement of commercial milestones, and up to mid-teens royalty payments based on potential net sales of XP23829 in the United States.

Dr. Mark Jackson, M.D., clinical professor of medicine, Dermatology, University of Louisville, stated, "Based on today's available treatments, physicians need additional oral medications that are both safe and effective for patients with psoriasis. Fumaric acid esters possess a unique anti-inflammatory mechanism of action and have been used to treat psoriasis in Germany for over 20 years. XP23829, a novel fumaric acid ester, has the potential to be a meaningful treatment option for patients with moderate-to-severe psoriasis."

"XP23829 complements our internal development efforts, which have primarily focused on the mild-to-moderate psoriasis segment to date. In other markets, fumarates have been used as first line choices of treatment prior to initiation of biologic therapies in patients with moderate-to-severe psoriasis. We intend to initiate the registration program for XP23829 as soon as feasible so that we can accelerate the availability of this important treatment choice for moderate-to-severe psoriasis patients in the U.S. market," said Raghav Chari, Executive Vice President, Proprietary Products Group, Dr. Reddy's Laboratories.

"We are very pleased to announce this agreement with Dr. Reddy's Laboratories," said Vincent J. Angotti, Chief Executive Officer, XenoPort, Inc. "As one of our key objectives for 2016, we were interested in finding a strong partner that would recognize the opportunity of this innovative therapy that we believe will make a significant difference in the lives of psoriasis and MS patients. We are now fully focused on our HORIZANT® (gabapentin enacarbil) Extended-Release Tablets commercialization effort."

The agreement is subject to review by the U.S. Government under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act, as amended, and will become effective only after clearing HSR review.

About XP23829
XP23829 is an investigational drug discovered by XenoPort. It is a novel, oral fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF). Fumaric acid ester compounds have shown immuno-modulatory and neuroprotective effects in cell-based systems and preclinical models of disease. TECFIDERA, which is approved for relapsing forms of MS in the United States and relapsing-remitting MS in the European Union and FUMADERM, which is approved in Germany for psoriasis, are based on another MMF prodrug known as dimethyl fumarate (DMF). XP23829 is protected by a U.S. composition-of-matter patent that currently has an expiration date of 2029.

In September 2015, XenoPort announced results of a Phase 2 clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis.

Another study looking at the prevalence of psoriatic arthritis, this one also takes enthesitis into consideration.

Quote:

---

Objective:
To estimate the prevalence of psoriatic arthritis (PsA) in primary care patients diagnosed as having psoriasis and to estimate the prevalence of musculoskeletal symptoms in psoriasis patients in primary care.

Methods:
We conducted a cross-sectional study in adult primary care patients with psoriasis. Responding patients reporting pain in joints, entheses, or the lower back were interviewed by telephone to determine eligibility and, if eligible, were invited for clinical evaluation. During clinical evaluation, skin, nails, joints, and entheses were assessed. Additionally, ultrasound of the enthesis was performed by an independent trained examiner if a patient had at least 1 tender enthesis (determined by the Leeds Enthesitis Index and the Maastricht Ankylosing Spondylitis Enthesitis Score). Patients who fulfilled the Classification of Psoriatic Arthritis (CASPAR) Study Group criteria were classified as having PsA.

Results:
We invited 2,564 psoriasis patients from databases of 97 participating general practitioners. Of 1,673 responders (65.2%), 841 (50.3%) were willing to participate. A total of 823 patients (32.1%) reported having musculoskeletal symptoms; 659 of these patients were determined to be eligible, 524 of whom were clinically evaluated. We identified 64 cases of established PsA and another 17 cases of newly diagnosed PsA, leading to a prevalence of 3.2% (95% confidence interval [95% CI] 2.5–3.9) among psoriasis patients in primary care. This prevalence would increase to 4.6% (95% CI 3.8–5.4) if PsA cases based on enthesitis were also taken into account.

Conclusion:
Among psoriasis patients in primary care, the prevalence of PsA is conservatively estimated to be 3.2%, increasing to 4.6% if enthesitis is taken into account. The prevalence of musculoskeletal symptoms among psoriasis patients is comparable with the prevalence of musculoskeletal symptoms in the general population.

This study looked at the risk of developing psoriatic arthritis in patients with psoriasis

Quote:

---

Objective:
To estimate the incidence of psoriatic arthritis (PsA) in patients with psoriasis, and to identify risk factors for its development.

Methods:
The study was designed as a prospective cohort study involving psoriasis patients who did not have a diagnosis of arthritis at the time of study enrollment. Information was collected about lifestyle habits, comorbidities, psoriasis activity, and medications. Patients who developed inflammatory arthritis or spondylitis were classified as having PsA if they fulfilled the criteria of the Classification of Psoriatic Arthritis Study group. The annual incidence of PsA was estimated using an event per person-years analysis. Cox proportional hazards models, involving fixed and time-dependent explanatory variables, were fitted to obtain estimates of the relative risk (RR) of the onset of PsA, determined in multivariate models stratified by sex and controlled for age at onset of psoriasis.

Results:
The data obtained from the 464 patients who were followed up for 8 years were analyzed. A total of 51 patients developed PsA during the 8 years since enrollment. The annual incidence rate of PsA was 2.7 cases (95% confidence interval 2.1–3.6) per 100 psoriasis patients. The following baseline variables were associated with the development of PsA in multivariate analysis: severe psoriasis (RR 5.4, P = 0.006), low level of education (university/college versus high school incomplete RR 0.22, P = 0.005; high school graduate versus high school incomplete RR 0.30, P = 0.049), and use of retinoid medications (RR 3.4, P = 0.02). In multivariate models with time-dependent variables, psoriatic nail pitting (RR 2.5, P = 0.002) and uveitis (RR 31.5, P = 0.0002) were associated with the development of PsA.

Conclusion:
The incidence of PsA in patients with psoriasis is higher than previously reported. A severe psoriasis phenotype, presence of nail pitting, low level of education, and uveitis are predictive of the development of PsA in patients with psoriasis.

Hi guys. Happy to join
Just curious, how many people here have tried brodalumab?

Hello all,

Looking forward to sharing information.